News Room
01
02
03
04
05
01
/
05
![](/Social/3317/image-thumb__3317__width424/repligen_default_twitter_card_image.png)
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
Repligen Corporation yoday announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device.The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal.
![](/_default_upload_bucket/8627/image-thumb__8627__width424/metenova_logo_acq.jpg)
Repligen completes the acquisition of Metenova
Repligen acquired Metenova, a leading Swedish innovator in magnetic mixing technology for biopharmaceutical production. This strategic step further strengthens Repligen's Fluid Management franchise, enriching our single-use mixing solutions and expanding our product range. Welcome, Metenova!
![](/_default_upload_bucket/8398/image-thumb__8398__width424/flexbiosys_1.png)
Repligen acquires FlexBiosys Inc.
Repligen today entered an agreement to acquire FlexBiosys Inc. of Branchburg, NJ. The acquisition is another step in building out Repligen’s Fluid Management franchise, adding a full range of single-use bioprocessing bags and assemblies to our product offering. The addition of FlexBiosys complements and vertically integrates our systems offering, providing a more complete single-use fluid management portfolio of products for our biopharmaceutical manufacturing customers. Welcome FlexBiosys!
![](/News%20Items/3654/image-thumb__3654__width424/RMP%20News%20Image.png)
Introducing the KrosFlo® KR2i RPM™ System
Monitor concentration during your UF/DF run with the new KrosFlo KR2i RPM System. Featuring in-line protein concentration management, you control your process with the power of the KrosFlo KR2i TFF System and insights from the CTech™ FlowVPX® System.
![](/Announcements/3389/image-thumb__3389__width424/Culpeo%20News%20item.png)
Expanding Process Analytics: Daylight Solutions
Repligen will assume responsibility for the commercialization of Culpeo®, as well as the development of future products and technologies in the fast-growing Process Analytics Technology (PAT) segment of the bioprocessing market.